Gautam Reddy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gautam Reddy has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Arka Chatterjee
From Divisions of Cardiovascular Diseases (G.R., A.C.) and Critical Care Medicine (K.L.), University of Alabama at Birmingham
2 shared publications- Brigitta C. Brott
University of Alabama at Birmingham, Birmingham, Alabama, USA
2 shared publications - Oluseun O. Alli
From the Division of Cardiovascular Diseases, The University of Alabama, Birmingham (G.R., J.E.D., S.P.S., O.O.A.); and Division of Cardiovascular Diseases, The Mayo Clinic, Rochester, MN (D.R.H., H.V.S.).
2 shared publications Steven G. Lloyd
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
2 shared publications- Vera Bittner
Division of Cardiovascular Disease, University of Alabama at Birmingham , Birmingham, AL
2 shared publications Allison Cabalka
Department of Cardiovascular Diseases. Mayo Clinic, Rochester, Minnesota
1 shared publication
Latest Publications
- 2 October 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (4) , 713-719
Effect of percutaneous paravalvular leak closure on hemolysis
Objective: To study the effect of percutaneous paravalvular leak closure on hemolysis.Background: Although transcatheter PVL closure reduces heart failure and mortality in symptomatic patients with paravalvular leaks (PVL), little is known about its effect on hemolysis.Methods: We retrospectively analyzed patients undergoing transcatheter mitral or aortic PVL closure (January 2005–December 2016) at Mayo Clinic. Patients with anemia or abnormal hemolysis markers (LDH, haptoglobin) were included in the analysis. The primary outcome was defined as hemoglobin increase ≥ 1.5 mg/dL, decrease in LDH above median or improvement in haptoglobin. Univariate and multivariate binary logistic regression modeling were used to determine predictors of successful treatment of hemolysis.Results: Final study population included 168 patients (130 [77%] mitral, 38 [23%] aortic PVL). Primary outcome occurred in 70 patients (42%). Hemoglobin increased by 1.74 ± 1.69 mg/dL in patients who reached primary outcome. 57/168 (34%) patients required blood transfusion prior to PVL closure compared to 35/168 (21%) postprocedure. The mean reduction in LDH was 403 U/L. Multivariate regression showed that patients with mechanical valves were more likely to have successful outcome (P = 0.044).Conclusion: Percutaneous PVL closure is associated with modest improvement in hemolysis markers, increase in hemoglobin levels and reduction in blood transfusion requirements. This benefit is most significant in patients with mechanical valves.
- 2 October 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (4) , 713-719
Effect of percutaneous paravalvular leak closure on hemolysis
Objective: To study the effect of percutaneous paravalvular leak closure on hemolysis.Background: Although transcatheter PVL closure reduces heart failure and mortality in symptomatic patients with paravalvular leaks (PVL), little is known about its effect on hemolysis.Methods: We retrospectively analyzed patients undergoing transcatheter mitral or aortic PVL closure (January 2005–December 2016) at Mayo Clinic. Patients with anemia or abnormal hemolysis markers (LDH, haptoglobin) were included in the analysis. The primary outcome was defined as hemoglobin increase ≥ 1.5 mg/dL, decrease in LDH above median or improvement in haptoglobin. Univariate and multivariate binary logistic regression modeling were used to determine predictors of successful treatment of hemolysis.Results: Final study population included 168 patients (130 [77%] mitral, 38 [23%] aortic PVL). Primary outcome occurred in 70 patients (42%). Hemoglobin increased by 1.74 ± 1.69 mg/dL in patients who reached primary outcome. 57/168 (34%) patients required blood transfusion prior to PVL closure compared to 35/168 (21%) postprocedure. The mean reduction in LDH was 403 U/L. Multivariate regression showed that patients with mechanical valves were more likely to have successful outcome (P = 0.044).Conclusion: Percutaneous PVL closure is associated with modest improvement in hemolysis markers, increase in hemoglobin levels and reduction in blood transfusion requirements. This benefit is most significant in patients with mechanical valves.
- 30 September 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 91 (5) , 975-983
Transcatheter aortic valve replacement for stenotic bicuspid aortic valves: Systematic review and meta analyses of observational studies
Objective: The aim of this study was to perform a systematic review and meta‐analyses of observational studies of transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve stenosis (BcAV).Background: TAVR for BcAV stenosis has been associated with an increased incidence of paravalvular leaks, valve malposition, pacemaker placement and all‐cause mortality. The conclusions drawn have been limited by small sample sizes. The use of TAVR for BcAV stenosis remains controversial.Methods: We searched multiple databases from the inception of the databases through September 30, 2016 for studies of TAVR for BcAV stenosis. We included all observational studies with more than one patient and at least 1 month of outcomes.Results: We analyzed 13 observational studies with 758 patients. Meta analyses showed device success rate of 95% [95% confidence interval (CI) 90.2% to 98.5%] and an early safety event in 16.9% [95% CI 12.2% to 22%]. At 30 days, moderate to severe paravalvular leak was seen in 12.2% [95% CI 3.1% to 24.8%] and new pacemaker implantation in 17.9% [95% CI 14.2% to 22%]. All‐cause mortality was 3.7% [95% CI 2.1% to 5.6%], which should be viewed in the context of an STS PROM of 5.0%.Conclusions: This analysis suggests that TAVR for BcAV is not associated with excess mortality. The incidence of paravalvular leaks and pacemaker implant is increased compared to tricuspid aortic valve cohorts undergoing TAVR, and operators should weigh these potential complications against the clinical benefit provided by TAVR for BcAV patients at high risk for surgical valve replacement.
- 30 September 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 91 (5) , 975-983
Transcatheter aortic valve replacement for stenotic bicuspid aortic valves: Systematic review and meta analyses of observational studies
Objective: The aim of this study was to perform a systematic review and meta‐analyses of observational studies of transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve stenosis (BcAV).Background: TAVR for BcAV stenosis has been associated with an increased incidence of paravalvular leaks, valve malposition, pacemaker placement and all‐cause mortality. The conclusions drawn have been limited by small sample sizes. The use of TAVR for BcAV stenosis remains controversial.Methods: We searched multiple databases from the inception of the databases through September 30, 2016 for studies of TAVR for BcAV stenosis. We included all observational studies with more than one patient and at least 1 month of outcomes.Results: We analyzed 13 observational studies with 758 patients. Meta analyses showed device success rate of 95% [95% confidence interval (CI) 90.2% to 98.5%] and an early safety event in 16.9% [95% CI 12.2% to 22%]. At 30 days, moderate to severe paravalvular leak was seen in 12.2% [95% CI 3.1% to 24.8%] and new pacemaker implantation in 17.9% [95% CI 14.2% to 22%]. All‐cause mortality was 3.7% [95% CI 2.1% to 5.6%], which should be viewed in the context of an STS PROM of 5.0%.Conclusions: This analysis suggests that TAVR for BcAV is not associated with excess mortality. The incidence of paravalvular leaks and pacemaker implant is increased compared to tricuspid aortic valve cohorts undergoing TAVR, and operators should weigh these potential complications against the clinical benefit provided by TAVR for BcAV patients at high risk for surgical valve replacement.
- Open Access
- 1 November 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 8 (11) , e003062
Coronary Artery Fistulae
- 1 November 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 8 (11) , e003062
Open AccessCoronary Artery Fistulae
- 16 June 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 131 (24) , e533
Letter by Reddy and Leesar Regarding Article “Assisted Beating of the Ischemic Heart: How to Manage the Pulseless ST-Segment–Elevation Myocardial Infarction Patient”
- 16 June 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 131 (24) , e533
Letter by Reddy and Leesar Regarding Article “Assisted Beating of the Ischemic Heart: How to Manage the Pulseless ST-Segment–Elevation Myocardial Infarction Patient”
- Open Access
- 30 April 2015
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 2, 8
Improved Right Ventricular Performance with Increased Tricuspid Annular Excursion in Athlete’s Heart
Background: Marathon runners (MTH) and patients with mitral regurgitation (MR) exhibit left ventricular (LV) overload, and LV geometric changes in these groups have been reported. In this study, right ventricular (RV) adaptation to chronic volume overload was evaluated in MTH and MR and normal controls together with interventricular septal remodeling and tricuspid annulus (TA) motion. Methods: A total of 60 age-matched subjects (including 19 MTH, 17 isolated chronic compensated MR patients and 24 normal subjects) underwent conventional cine and tagged cardiac magnetic resonance imaging. Myocardial strain and curvature were computed on the interventricular septum and RV free wall. A dual-propagation technique was applied to construct RV volume-time curves for a single cardiac cycle. Similarly, the tricuspid annulus was tracked throughout the cardiac cycle to create displacement over time curve. Results: Septal curvature was significantly lower in MTH and MR compared to controls. No significant differences in RV free wall strain or RV ejection fraction were noted amongst the 3 groups. However, longitudinal TA excursion was significantly higher in MTH compared to controls (p=0.0061). The peak late diastolic TA velocity in MR was significantly faster than MTH (p=0.0031) and controls (p=0.020). Conclusions: Increased TA kinetics allows for improved RV performance in MTH. Septal remodeling was observed in both MR and MTH, therefore a direct relationship of septal remodeling to TA kinetics in athlete’s heart could not be elucidated in this study.
- 30 April 2015
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 2, 8
Open AccessImproved Right Ventricular Performance with Increased Tricuspid Annular Excursion in Athlete’s Heart
Background: Marathon runners (MTH) and patients with mitral regurgitation (MR) exhibit left ventricular (LV) overload, and LV geometric changes in these groups have been reported. In this study, right ventricular (RV) adaptation to chronic volume overload was evaluated in MTH and MR and normal controls together with interventricular septal remodeling and tricuspid annulus (TA) motion. Methods: A total of 60 age-matched subjects (including 19 MTH, 17 isolated chronic compensated MR patients and 24 normal subjects) underwent conventional cine and tagged cardiac magnetic resonance imaging. Myocardial strain and curvature were computed on the interventricular septum and RV free wall. A dual-propagation technique was applied to construct RV volume-time curves for a single cardiac cycle. Similarly, the tricuspid annulus was tracked throughout the cardiac cycle to create displacement over time curve. Results: Septal curvature was significantly lower in MTH and MR compared to controls. No significant differences in RV free wall strain or RV ejection fraction were noted amongst the 3 groups. However, longitudinal TA excursion was significantly higher in MTH compared to controls (p=0.0061). The peak late diastolic TA velocity in MR was significantly faster than MTH (p=0.0031) and controls (p=0.020). Conclusions: Increased TA kinetics allows for improved RV performance in MTH. Septal remodeling was observed in both MR and MTH, therefore a direct relationship of septal remodeling to TA kinetics in athlete’s heart could not be elucidated in this study.
- 28 April 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 131 (17) , 1529-1530
Left Atrial Mural Endocarditis Secondary to Mitral Valve Jet Lesion
- 28 April 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 131 (17) , 1529-1530
Left Atrial Mural Endocarditis Secondary to Mitral Valve Jet Lesion
- Open Access
- 6 January 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 131 (1) , e1-e2
Transdiaphragmatic Rupture of Hepatic Abscess Producing Purulent Pericarditis and Pericardial Tamponade
- 6 January 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 131 (1) , e1-e2
Open AccessTransdiaphragmatic Rupture of Hepatic Abscess Producing Purulent Pericarditis and Pericardial Tamponade
- Open Access
- 17 June 2014
- Published by Wolters Kluwer Health in Circulation
- Vol. 129 (24)
Left Anterior Descending Coronary Artery Occlusion Secondary to Metastatic Squamous Cell Carcinoma Presenting as ST-Segment–Elevation Myocardial Infarction
- 17 June 2014
- Published by Wolters Kluwer Health in Circulation
- Vol. 129 (24)
Open AccessLeft Anterior Descending Coronary Artery Occlusion Secondary to Metastatic Squamous Cell Carcinoma Presenting as ST-Segment–Elevation Myocardial Infarction
- 31 January 2014
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 85 (5) , 925-929
Percutaneous valvuloplasty for severe bioprosthetic tricuspid valve stenosis in the setting of infective endocarditis
Bioprosthetic tricuspid valve stenosis as a sequela of infective endocarditis is extremely rare. We describe the case of a 29‐year‐old male patient with a history of intravenous drug use and two previous bioprosthetic tricuspid valve placements who presented with recurrent endocarditis and severe tricuspid stenosis. He was deemed extremely high risk for redo valve replacement surgery. Intracardiac ultrasound‐guided balloon valvuloplasty was performed with good clinical outcome. We believe that interventional treatment of prosthetic valvular stenosis in the setting of endocarditis is a reasonable therapeutic choice when open surgical repair is associated with prohibitively high mortality. This can be performed either as destination therapy or as a bridge to valve replacement. The use of intracardiac ultrasound provided additive information to that obtained by transthoracic and transesophageal echocardiography.
- 31 January 2014
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 85 (5) , 925-929
Percutaneous valvuloplasty for severe bioprosthetic tricuspid valve stenosis in the setting of infective endocarditis
Bioprosthetic tricuspid valve stenosis as a sequela of infective endocarditis is extremely rare. We describe the case of a 29‐year‐old male patient with a history of intravenous drug use and two previous bioprosthetic tricuspid valve placements who presented with recurrent endocarditis and severe tricuspid stenosis. He was deemed extremely high risk for redo valve replacement surgery. Intracardiac ultrasound‐guided balloon valvuloplasty was performed with good clinical outcome. We believe that interventional treatment of prosthetic valvular stenosis in the setting of endocarditis is a reasonable therapeutic choice when open surgical repair is associated with prohibitively high mortality. This can be performed either as destination therapy or as a bridge to valve replacement. The use of intracardiac ultrasound provided additive information to that obtained by transthoracic and transesophageal echocardiography.
- 6 November 2012
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 15 (1) , 33-40
LDL Lowering After Acute Coronary Syndrome: Is Lower Better?
Low density lipoprotein cholesterol (LDL-C) levels are a major risk factor for the development of acute coronary syndrome (ACS) and for recurrent events after ACS. Lowering LDL-C after ACS leads to a significant reduction in recurrent events and overall mortality. A lower limit at which LDL-C reduction fails to decrease risk has not been determined, and lowering LDL-C below current guideline-defined targets may provide incremental benefit. While the absolute risk is small, more intensive statin therapy is associated with a higher incidence of myopathy, rhabdomyolysis, liver enzyme abnormalities and incident diabetes, but not with an increase in malignancies or all-cause mortality. It is important that clinicians recognize ACS patients as being at very high risk, and provide these patients with intensive lifestyle and pharmacologic therapy for all modifiable risk factors. Within this framework, either a strategy of “intensive statin treatment after ACS” or a strategy of “aggressive LDL-C targets after ACS” would be appropriate based on currently available data. Combination lipid-lowering therapy does not have a firm evidence base at this point, but may be appropriate in patients with limited statin tolerance or very high baseline LDL-C levels. Newer therapies, such as LDL apheresis, antisense oligonucleotide sequences to apolipoprotein B (apoB) and preprotein convertase subtilin kexin 9 (PCSK9) inhibitors, are currently in clinical trials and may represent important advances in LDL-C lowering therapy in the future.
- 6 November 2012
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 15 (1) , 33-40
LDL Lowering After Acute Coronary Syndrome: Is Lower Better?
Low density lipoprotein cholesterol (LDL-C) levels are a major risk factor for the development of acute coronary syndrome (ACS) and for recurrent events after ACS. Lowering LDL-C after ACS leads to a significant reduction in recurrent events and overall mortality. A lower limit at which LDL-C reduction fails to decrease risk has not been determined, and lowering LDL-C below current guideline-defined targets may provide incremental benefit. While the absolute risk is small, more intensive statin therapy is associated with a higher incidence of myopathy, rhabdomyolysis, liver enzyme abnormalities and incident diabetes, but not with an increase in malignancies or all-cause mortality. It is important that clinicians recognize ACS patients as being at very high risk, and provide these patients with intensive lifestyle and pharmacologic therapy for all modifiable risk factors. Within this framework, either a strategy of “intensive statin treatment after ACS” or a strategy of “aggressive LDL-C targets after ACS” would be appropriate based on currently available data. Combination lipid-lowering therapy does not have a firm evidence base at this point, but may be appropriate in patients with limited statin tolerance or very high baseline LDL-C levels. Newer therapies, such as LDL apheresis, antisense oligonucleotide sequences to apolipoprotein B (apoB) and preprotein convertase subtilin kexin 9 (PCSK9) inhibitors, are currently in clinical trials and may represent important advances in LDL-C lowering therapy in the future.